WO1995024928A3 - Heparin-binding growth factors for gene therapy and anterior eye disorders - Google Patents
Heparin-binding growth factors for gene therapy and anterior eye disorders Download PDFInfo
- Publication number
- WO1995024928A3 WO1995024928A3 PCT/US1995/003448 US9503448W WO9524928A3 WO 1995024928 A3 WO1995024928 A3 WO 1995024928A3 US 9503448 W US9503448 W US 9503448W WO 9524928 A3 WO9524928 A3 WO 9524928A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugates
- heparin
- nucleic acid
- binding growth
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95916103A EP0776218A2 (en) | 1994-03-15 | 1995-03-15 | Heparin-binding growth factors for gene therapy and anterior eye disorders |
JP7524212A JPH09510352A (en) | 1994-03-15 | 1995-03-15 | Heparin-binding growth factor for gene therapy and anterior eye disease |
AU22724/95A AU702323B2 (en) | 1994-03-15 | 1995-03-15 | Heparin-binding growth factors for gene therapy and anterior eye disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21344694A | 1994-03-15 | 1994-03-15 | |
US21344794A | 1994-03-15 | 1994-03-15 | |
US08/213,447 | 1994-03-15 | ||
US08/213,446 | 1994-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995024928A2 WO1995024928A2 (en) | 1995-09-21 |
WO1995024928A3 true WO1995024928A3 (en) | 1995-10-12 |
Family
ID=26908098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/003448 WO1995024928A2 (en) | 1994-03-15 | 1995-03-15 | Heparin-binding growth factors for gene therapy and anterior eye disorders |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1188448A3 (en) |
JP (1) | JPH09510352A (en) |
AU (1) | AU702323B2 (en) |
CA (1) | CA2185671A1 (en) |
WO (1) | WO1995024928A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008293A1 (en) * | 1992-12-23 | 1996-03-21 | Patrick Edison Kane | Injection molded water-soluble golf ball |
US6037329A (en) | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
AU3374795A (en) * | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
WO1996008274A2 (en) * | 1994-09-13 | 1996-03-21 | Prizm Pharmaceuticals, Inc. | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
CA2221269A1 (en) * | 1995-05-16 | 1996-11-21 | Lois A. Chandler | Compositions containing nucleic acids and ligands for therapeutic treatment |
US6403557B1 (en) | 1996-11-27 | 2002-06-11 | Human Genome Sciences, Inc. | Fibroblast growth factor-13 |
US5728546A (en) | 1995-06-05 | 1998-03-17 | Human Genome Sciences, Inc. | Fibroblast growth factor 13 |
GB9601640D0 (en) * | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
US5877282A (en) * | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
SE513149C2 (en) * | 1997-12-05 | 2000-07-17 | Katarina Edwards | Drug distribution system with two-step targeting, to specific cells or tissue and to its cell nucleus |
JP2001526239A (en) | 1997-12-22 | 2001-12-18 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | Keratinocyte growth factor-2 preparation |
US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
CA2320515A1 (en) | 1998-02-13 | 1999-08-19 | Human Genome Sciences, Inc. | Therapeutic uses of keratinocyte growth factor-2 |
DE69903612T2 (en) * | 1998-03-12 | 2003-07-10 | Genentech Inc | USE OF FGF-5 POLYPETIDES TO PREVENT THE DEATH OF RETINAL NEURONES AND TREATMENT OF Ocular DISEASES |
US6331523B1 (en) | 1998-03-12 | 2001-12-18 | Genentech, Inc. | Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 |
US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
US6506365B1 (en) * | 2000-09-25 | 2003-01-14 | Baxter Aktiengesellschaft | Fibrin/fibrinogen binding conjugate |
US20100287625A1 (en) * | 2006-01-19 | 2010-11-11 | Universite De Liege | Vegf variants |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
EP2043662B1 (en) * | 2006-07-26 | 2015-09-09 | Intrexon Corporation | Methods and compositions for treating disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012597A1 (en) * | 1989-04-27 | 1990-11-01 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
WO1991018012A1 (en) * | 1990-05-14 | 1991-11-28 | Biospan Corporation | Cell internalizable conjugates and complexes including intracellularly cleavable moieties |
WO1992004918A1 (en) * | 1990-09-19 | 1992-04-02 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates |
WO1993025688A1 (en) * | 1992-06-16 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Recombinant production of saporin-containing proteins |
WO1995003831A1 (en) * | 1993-08-02 | 1995-02-09 | Prizm Pharmaceuticals, Inc. | Monogenous preparations of cytotoxic conjugates |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2221269A1 (en) * | 1995-05-16 | 1996-11-21 | Lois A. Chandler | Compositions containing nucleic acids and ligands for therapeutic treatment |
-
1995
- 1995-03-15 WO PCT/US1995/003448 patent/WO1995024928A2/en not_active Application Discontinuation
- 1995-03-15 JP JP7524212A patent/JPH09510352A/en not_active Ceased
- 1995-03-15 EP EP01125266A patent/EP1188448A3/en not_active Withdrawn
- 1995-03-15 AU AU22724/95A patent/AU702323B2/en not_active Ceased
- 1995-03-15 EP EP95916103A patent/EP0776218A2/en not_active Withdrawn
- 1995-03-15 CA CA002185671A patent/CA2185671A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012597A1 (en) * | 1989-04-27 | 1990-11-01 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
US5191067A (en) * | 1989-04-27 | 1993-03-02 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
WO1991018012A1 (en) * | 1990-05-14 | 1991-11-28 | Biospan Corporation | Cell internalizable conjugates and complexes including intracellularly cleavable moieties |
WO1992004918A1 (en) * | 1990-09-19 | 1992-04-02 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates |
WO1993025688A1 (en) * | 1992-06-16 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Recombinant production of saporin-containing proteins |
WO1995003831A1 (en) * | 1993-08-02 | 1995-02-09 | Prizm Pharmaceuticals, Inc. | Monogenous preparations of cytotoxic conjugates |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, vol. 111, no. 1, 3 July 1989, Columbus, Ohio, US; abstract no. 1549, DAUCHEL, M. C. ET AL: "Modulation of mitogenic activity and cellular binding of basic fibroblast growth factor by basic proteins" * |
CHEMICAL ABSTRACTS, vol. 116, no. 15, 13 April 1992, Columbus, Ohio, US; abstract no. 149628, FATTOM, A. ET AL: "Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2- pyridyldithio)propionate" * |
INFECT. IMMUN. (1992), 60(2), 584-9 CODEN: INFIBR;ISSN: 0019-9567 * |
J. CELL. BIOCHEM. (1989), 39(4), 411-20 CODEN: JCEBD5;ISSN: 0730-2312 * |
MICHAEL WESTBY ET AL.: "SEPARATION AND CHARACTERIZATION OF RECOMBINANT PRORICIN CONTAINING AN ALTERNATIVE PROTEASE-SENSITIVE LINKER SEQUENCE.", BIOCONJUGATE CHEMISTRY, vol. 3, WASHINGTON US, pages 375 - 381 * |
Also Published As
Publication number | Publication date |
---|---|
WO1995024928A2 (en) | 1995-09-21 |
EP1188448A3 (en) | 2002-04-17 |
AU2272495A (en) | 1995-10-03 |
EP1188448A2 (en) | 2002-03-20 |
JPH09510352A (en) | 1997-10-21 |
CA2185671A1 (en) | 1995-09-21 |
AU702323B2 (en) | 1999-02-18 |
EP0776218A2 (en) | 1997-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1188448A3 (en) | Heparin-binding growth factors for gene therapy and anterior eye disorders | |
Fawell et al. | Tat-mediated delivery of heterologous proteins into cells. | |
Bergan et al. | Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy | |
Henderson et al. | Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death | |
JP3222461B2 (en) | New protein-polycation conjugate | |
EP0759694A4 (en) | Method for in vivo delivery of therapeutic agents via liposomes | |
US20050271672A1 (en) | Cytotoxic CD44 antibody immunoconjugates | |
NO301932B1 (en) | Transferrin polycation conjugates and their use | |
IE872553L (en) | Recombinant pseudomonas exotoxins | |
EP0329184A3 (en) | Antimers and antimeric conjugation | |
YU16600A (en) | Pharmaceutical composition containing plasma protein | |
US5478804A (en) | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates | |
CA2373721A1 (en) | Compounds that bind her2 | |
ATE280833T1 (en) | CATIONIC LIPID/DNA COMPLEXES FOR TARGETTING GENES | |
IE900931L (en) | Genetic units for inhibiting the function of rna | |
US20110200599A1 (en) | Sustained drug delivery system | |
DE4104186A1 (en) | NEW COMPLEXES INCLUDING ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID | |
WO1996008274A3 (en) | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents | |
US6089234A (en) | Method for destroying residual lens epithelial cells | |
AU770963B2 (en) | New oligomeric conjugates liable to transfer biological molecules into cells | |
DE69637154T2 (en) | HIGHLY EFFICIENT TISSUE-SPECIFIC SYSTEM FOR THE PREPARATION OF COMPOUNDS USING A STREPTAVIDINE PROTEIN A FUSION PROTEIN | |
WO1998039293A3 (en) | 13-thia prostaglandins for use in glaucoma therapy | |
EP0577648B1 (en) | Novel protein polycation conjugates | |
EP0868198A1 (en) | FC$g(e)-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
WO1999055861A3 (en) | Fibroblast growth factor mutein compositions and methods of use therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2185671 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995916103 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995916103 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995916103 Country of ref document: EP |